TAMPA, Fla., Nov. 8, 2004 (PRIMEZONE) -- Southwestern Medical Solutions, Inc. (Pink Sheets:SWNM) is pleased to announce that Physicians STAT Laboratories has requested that SWMS package a specific 9-panel model of its Labguard Accuchec(tm) diagnostic testing device.
This new 9-panel version of the Company's specimen collection/testing device will offer unique on-site testing capabilities that are applicable to many sectors, including screening of job applicants, probation/parolees screening, health screening, as well as local, state and federal governments, which mandate myriad tests/screenings to improve workplace efficiency and maintain safety standards, monitor probation, and check the general health of employees.
THE NINE-PANEL TEST -- The new 9-panel test will be offered in a variety of formats that will facilitate the screening for of a wide range of components/substances including: Alcohol Use, Allergies, Mold, Blood Type, Cancers, Cholesterol, Diabetes Diseases, DNA, Genetics, Drug Use, Hazardous Chemicals, HIV, Hormones, Infertility, Menopause, Thyroid, Tobacco Use, etc.
ADDRESSING A CRITICAL NEED -- Southwestern Medical's proposed 9-panel test will fulfill the need of many specimen testing/screening sectors to achieve a more comprehensive on-site test, with high accuracy, rigid control, utmost safety and efficiency at an attractively affordable price. Management is therefore confident that the 9-panel Labguard Accuchec(tm) will meet with a strong market reception.
LABGUARD ACCUCHECK(tm) -- The prevalence of on-site testing of employees, job applicants, military personnel, public service workers, prison inmates and parolees, students and athletes to detect the use of illicit substances has exploded across North America during the past decade. Southwestern Medical's technology directly addresses inefficiencies and unwarranted risks associated with procedures and devices now in use, and promises to catapult the Company into the role of a key supplier in this large market.
SOUTHWESTERN MEDICAL HAS THE SOLUTION -- The Company's proprietary Labguard Accucheck(tm) on-site collection and diagnostic testing technology represents a revolutionary approach that ensures greater safety and convenience for diagnostic testing administrators at an attractive, market-competitive price. Currently in the final prototype stage, Labguard Accucheck(tm) has already attracted expressions of strong interest from several major medical-device distribution companies, both in the U.S. and abroad. Numerous applications of the Labguard Accucheck(tm) to address specific market needs are currently in the design, prototype and/or testing stages.
The statements made in this press release, which are not historical facts, contain forward-looking statements concerning potential developments affecting the business, prospects, financial conditions and other aspects of the company to which this release pertains. The actual results of the specific items described in the release, and the company's operations generally, may differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's dependence on third parties, general market and economic conditions, technical factors, the availability of outside capital, receipt of revenues and other factors, many of which are beyond the control of the company. The company disclaims any obligation to update information contained in any forward- looking statement.